CML-MPN Associated studies

Open studies

 Short name H-134
 Study title A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation.
 Participants ZNA Stuivenberg, UZ Gasthuisberg, AZ Delta, AMC, VUMC, AZ Maastricht, Radboudumc, Erasmus MC

 

Short name H-142
Study title Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response.
Participants Cliniques Universitaires St. Luc, Meander MC, VUMC, Reinier de Graaf Gasthuis, Jeroen Bosch ziekenhuis, A. Schweitzer ZH, Dordwijk, Atrium MC loc Heerlen, Spaarne ziekenhuis, Radboudumc, Orbis Medisch Centr

 

Short name Hovon-associated TARGET study
Study title Individualized dosing of fludarabine during innate allo SCT; A randomized phase II study
Participants

UMCU, LUMC

Other studies, not Hovon initiated

Short name NAUT
Study title 2nd TKI-stop After 2 Years Nilotinib Pre-treatment in Patients With First Unsuccessful Treatment Discontinuation in CML

 

Short name DASTOP2
Study title Persistence of major molecular remission in chronic myeloid leukemia after a second stop of TKI treatment in patients who failed an initial stop attempt: A prospective multicenter study

 

Short name

Mast cells and fibrosis in MPN (in vitro studie)

Participants

Erasmus MC

Other studies: Pharmacy-initiated study

Short name MANIFEST
Study title

A phase 1/2 study of CPI-0610, a small molecule inhibitor of BET proteins: Phase 1 (dose escalation of CPI-0610 in patients with hematological malignancies) and Phase 2 (dose expansion of CPI-0610 with and without ruxolitinib in patients with myelofibrosis)

Participants Erasmus MC, VUMC
Short name CINC424BIC04 polycythemia vera:
Study title

An international multi-centric observational study on the use of ruxolitinib in the treatment of patient with polycythemia vera resistant or intolerant to hydroxyurea.

Participants Erasmus MC
Short name FEDR-MF-002 Freedom 2 studie (Celgene/BMS)
Study title

2de lijn bij ruxolitinib resistente of intolerante patienten met myelofibrose

Participants Radboudumc
Short name ADORE (CINC424H12201)
Study title

Gerandomiseerde fase I/II studie ter beoordeling van veiligheid en werkzaamheid van nieuwe ruxolitinib combinaties voor patienten met refractaire myelofibrose

Participants VUMC, Erasmus MC

Pending studies

Short name M16-91-Transform 1 studie (Abbvie)
Study title

Upfront behandeling bij patienten met myelofibrose

Participants Radboudumc
Short name

Italfarmaco: Givinostat in PV

Participants Radboudumc
Short name ACE-536-MF-002
Study title

The independence trial luspatercept versus placebo + BSC (patienten die al behandeld zijn met ruxolitinib); fase III

Participants UMC Groningen
Short name Transform-1 M16-191
Study title

Ruxo-navitoclax versus ruxolitinib (patienten die nooit ruxolitinib hebben gehad); fase III

Participants UMC Groningen

 

Up